Source: Eur Respir J 2015; 46: 1548-1550



Rating:

Share or cite this content

Citations should be made in the following way:
Remon Jordi, Gorham Julie, Besse Benjamin, Sculier Jean-Paul. Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients?. Eur Respir J 2015; 46: 1548-1550

Member's Comments

No comment yet.

Related content which might interest you: Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer Source: Eur Respir J 2010; 36: 885-892 Year: 2010 Soluble non-invasive markers in non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005 Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival Source: Eur Respir J 2011; 37: 617-623 Year: 2011 Quantification of telomerase activity is important in predicting prognosis of patients with non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 482s Year: 2005 CHD4 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor cell proliferation Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 A non-small cell lung cancer modelling by endogenous κ-ras manipulation Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection Year: 2005 Serum hepcidin and iron are associated with non-small cell lung cancer stage Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Are there any peculiarities in tumour behavior and different tumour markers expression in nonsmall cell lung cancer? Source: Eur Respir J 2001; 18: Suppl. 33, 232s Year: 2001 Should there be a specific management for large cell neuroendocrine carcinoma? Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005 Does the incorporation of new generation cytotoxic agent improve the overall outcome in inoperable nonsmall cell lung cancer (NSCLC)? Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003 New treatment options for nonsmall cell lung cancer and small cell lung cancer Source: Annual Congress 2006 - PG12 - Small cell lung cancer management Year: 2006 Treatment of  non-small cell lung cancer (NSCLC) - the state of the art and beyond Source: International Congress 2017 – State of the art session: "Lung cancer" Year: 2017 Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo). Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 Choice of endogenous control for gene expression in nonsmall cell lung cancer Source: Eur Respir J 2005; 26: 1002-1008 Year: 2005 T790M-mutation in EGFR progressive non-small cell lung cancer, role of re-biopsy and ctDNA analysis Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017 Expression of βig-h3 as a marker of local tumor invasion in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006